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Interleukin-1 (IL-1) is a major “alarm” upstream pro-inflammatory cytokine that also affects
immunity and hematopoiesis by inducing cytokine cascades. In the tumor arena, IL-1 is pro-
duced by malignant or microenvironmental cells. As a pleiotropic cytokine, IL-1 is involved
in tumorigenesis and tumor invasiveness but also in the control of anti-tumor immunity.
IL-1α and IL-1β are the major agonists of IL-1, while IL-1Ra is a physiological inhibitor of pre-
formed IL-1. In their secreted form, IL-1α and IL-1β bind to the same receptors and induce
the same biological functions, but IL-1α and IL-1β differ in their compartmentalization within
the producing cell or the microenvironment. IL-1β is only active in its processed, secreted
form, and mediates inflammation, which promotes carcinogenesis, tumor invasiveness,
and immunosuppression, whereas IL-1α is mainly cell-associated and in the tumor context,
when expressed on the cell membrane, it stimulates anti-tumor cell immunity manifested
by tumor regression. In the tumor milieu, extracellular levels of IL-1α are usually low and do
not stimulate broad inflammation that promotes progression. Immunosuppression induced
by IL-1β in the tumor microenvironment, mainly through MDSC induction, usually inhibits
or masks anti-tumor cell immunity induced by cell-associated IL-1α. However, in different
tumor systems, redundant or unique patterns of IL-1α and IL-1β expression and function
have been observed. Recent breakthroughs in inflammasome biology and IL-1β process-
ing/secretion have spurred the development of novel anti-IL-1 agents, which are being used
in clinical trials in patients with diverse inflammatory diseases. Better understanding of the
integrative role of IL-1α and IL-1β in distinct malignancies will facilitate the application of
novel IL-1 modulation approaches at the bedside, in cancer patients with minimal residual
disease (MRD), as an adjunct to conventional approaches to reduce the tumor burden.
Keywords: IL-1, carcinogenesis, tumor invasiveness, tumor-host interactions, immunogenicity, anti-tumor immu-
nity, immunotherapy
EXPRESSION AND SECRETION OF IL-1α AND IL-1β – THE
MAJOR IL-1 AGONISTIC MOLECULES
The IL-1 family consists of 11 agonist and antagonist molecules
that are centrally involved in regulating inflammatory responses.
These include IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-1Ra, IL-36α,
IL-36β IL-36γ, and IL-38 [reviewed in Ref. (1–7)]. Here, we will
mainly focus on the two major IL-1 agonistic molecules, i.e., IL-
1α and IL-1β, and IL-1 receptor antagonist (IL-Ra), which is a
physiological inhibitor of IL-1 signaling.
IL-1α and IL-1β are synthesized as precursors of 31 kDa that
are further processed by proteases to their mature secreted 17 kDa
forms. IL-1 differs from most other cytokines by lack of a signal
sequence, thus not passing through the endoplasmic reticulum-
Golgi pathway; its mechanisms of secretion are not yet completely
understood. IL-1Ra, which has a signal peptide, is secreted in
the ER-Golgi exocytic pathway. Generally, IL-1 is produced and
secreted by various cell types upon inflammatory or stress condi-
tions, predominantly by myeloid cells, which display the strongest
capacity to produce and secrete IL-1. Stimulation of IL-1 pro-
duction occurs through signaling of Toll-like receptors (TLRs),
which recognize conserved microbial molecules of pathogens, i.e.,
pathogen-associated molecular patterns (PAMPs) [reviewed in
Ref. (8–10)] as well as endogenous molecules, which are products
of damaged cells, termed danger-associated molecular patterns
(DAMPs) [reviewed in Ref. (11–13)]. The activation of TLR sig-
naling via the NF-κB pathway leads to the generation of many
cytokines; IL-1 is a central cytokine produced by this pathway. Sig-
naling through surface IL-1Rs and most of the TLRs is common
and converges from MyD88 to NF-κB activation and induction of
an inflammatory response, including expression of IL-1.
PROCESSING OF IL-1β
The IL-1β-converting enzyme (ICE), or caspase-1, is a cysteine
protease, that is activated in the cytosol on the inflammasome plat-
form, and subsequently cleaves the inactive precursors of IL-1β,
IL-18, and IL-33 into their mature secreted forms (2, 3, 14–18).
PROCESSING OF IL-1α
The precursor of IL-1α (ProIL-1α) is processed by the Ca2+-
dependent protease calpain into the mature 17 kDa form and the
16 kDa N-terminal cleavage product – the propiece of IL-1α, also
termed IL-1α N-terminal peptide (IL-1NTP). The latent form of
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calpain is activated in cells under inflammatory conditions and
especially upon loss of plasma membrane integrity, which occurs
during necrosis (19). However, intracellular ProIL-1α is present
in many cells because they contain calpain inhibitors and are
thus unable to process and secrete IL-1α. Other proteases, such
as elastase, chymase, or Granzyme B can also process ProIL-1α
into smaller molecules with high inflammatory potential (20–
22). Recently some involvement of the inflammasome in IL-1α
secretion has been demonstrated (23–25). A biologically active
membrane-associated form of IL-1α (23 kDa), which is anchored
to the membrane via a mannose-like receptor, has been demon-
strated in activated cells that express the cytokine. However, it is
not clear how IL-1α is inserted in the membrane.
IL-1 RECEPTORS
IL-1α and IL-1β signal through the same IL-1Rs, which belong
to the immunoglobulin (Ig) supergene family and are abun-
dantly expressed on many cell types. IL-1R of type I (IL-1R1)
(80 kDa) is a signaling receptor, whereas the IL-1R of type II (IL-
1R2) (68 kDa) serves as a decoy target, acting to reduce excessive
amounts of IL-1 [reviewed in Ref. (1–7)]. Following the binding
of IL-1 to IL-1R1, a second chain, i.e., the IL-1R acceptor pro-
tein (IL-1RAcP) is recruited. This heterodimeric complex triggers
IL-1 signaling by activating the IL-1 receptor-associated kinase
(IRAK) and ultimately leads to activation of NF-κB and its tar-
get genes. On the contrary, IL-1R2 and the IL-1Ra do not form
this heterodimeric complex with the IL-1RAcP and therefore do
not recruit IRAK. Signaling through surface IL-1R1 represents
an evolutionary conserved mechanism homologous to the TLR
pathway.
MAJOR BIOLOGICAL ACTIVITIES OF IL-1
EFFECTS OF IL-1 ON INFLAMMATORY RESPONSES
IL-1α and IL-1β are defined as “alarm cytokines” that are secreted
by macrophages and initiate inflammatory responses, by induc-
ing a cascade of other pro-inflammatory genes [reviewed in Ref.
(1–7)]. Of major importance are cyclooxygenase type 2 (COX-
2), inducible nitric oxide synthase (iNOS), chemokines/cytokines,
and matrix metalloproteinases (MMPs). The IL-1 molecules stim-
ulate their own and each other’s production; this represents an
important amplification loop of the inflammatory response. Also,
IL-1 increases the expression of integrins on endothelial cells, stro-
mal cells, and leukocytes and thereby promotes cell infiltration into
inflamed tissues.
Recently, the unique alarmin function of ProIL-1α in sterile
inflammation has been described by us and others (26–30). In
tissue cells, such as epithelial cells, endothelial cells, and fibrob-
lasts, ProIL-1α is located in the cytosol and nucleus. Upon stress
induction, expression of ProIL-1α increases and it translocates
into the nucleus, where it is bound to chromatin in a highly
dynamic manner. In stressed cells, i.e., in hypoxic conditions,
ProIL-1α expression is initially increased, with the involvement of
the transcription factors HIF-1α and HIF-1β. Upon necrotic cell
death, ProIL-1α is released and induces inflammation (31). How-
ever, following apoptotic death, the mobility of IL-1α is greatly
reduced, it concentrates in dense nuclear foci and is not released
into the environment (27). This represents a novel mechanism
that explains why inflammatory responses are not generated upon
apoptosis. Necrotic cells lacking IL-1α failed to induce this early
inflammatory response. The early infiltrate found in Matrigel
plugs containing lysates of necrotic cells consists mainly of neu-
trophils and myeloid progenitor cells; recruitment of cells is via
IL-1R1 signaling (27, 29). Macrophages infiltrate such Matrigel
plugs at later times and they actively secrete IL-1β, which termi-
nates inflammation, resulting in wound healing and restoration
of tissue homeostasis (29). These results indicate significant dif-
ferences in the capacity of the major IL-1 agonistic molecules to
alarm inflammatory cells, thereby controlling the inflammatory
response. Recently, a novel mechanism to control IL-1α activity in
necrotic cells has been described by Zheng et al. (21) and reviewed
in Ref. (22). Zheng found that under normal conditions, IL-1α is
synthesized as a p33 precursor that is sequestered in the cytosol
by IL-1R2 where it cannot be cleaved by proteases or activate IL-
1R1 signaling. However, after inflammasome activation, IL-1R2
can be cleaved by caspase-1 and ProIL-1α can be released and
further processed by calpain to the highly active p17 mature IL-
1α form. Previously, it was thought that ProIL-1α and mature
IL-1α are active to the same extent. However, this study demon-
strated that the affinity of mature IL-1α to IL-1R1 is about 50
times higher than that of ProIL-1α; in accordance, their biological
activity significantly differs (22). Moreover, necrosis-induced IL-
1α activity is tightly controlled in a cell type-specific manner (21).
Thus, in cell types with a silent necrotic phenotype, IL-1R2 remains
associated with ProIL-1α. In contrast, in cells with an inflamma-
tory, necrotic phenotype, IL-1R2 is either absent or caspase-1 is
activated before necrosis. Overall, the extent of inflammation in
damaged tissues depends on the concentration of cleaved IL-1α,
as well as the local expression of IL-1R1. This control mechanism
evolved in order to prevent exacerbation of inflammation induced
by necrotic cells in tissues with limited regenerative capacity, such
as kidney, heart, and brain (21, 32). These findings suggested that
sterile inflammation can occur even without activation of IL-1β.
Other studies have also demonstrated inflammasome-dependent
IL-1α release in sterile inflammation, which may further lead to
ProIL-1β expression, caspase-1-dependent processing and release
[reviewed in Ref. (2, 22)].
EFFECTS OF IL-1 ON IMMUNE RESPONSES
As a pleiotropic cytokine, IL-1 has diverse potentiating effects on
the proliferation, differentiation, and function of various innate
(NK cells, macrophages, granulocytes etc.), as well as specific
immunocompetent cells (T and B cells) [reviewed in Ref. (1–
7)]. Most pronounced are the effects of IL-1 on T cell activation.
Initially, IL-1 was characterized as “the classical” co-stimulatory
cytokine for T cell proliferation, inducing IL-2 secretion and
expression of high affinity IL-2Rs by activated T cells (33). Recent
studies by the Paul group demonstrated that IL-1β induces a
robust and durable expansion of naïve and memory CD4+ T
cells (Th1, Th2, and Th17) in response to antigen stimulation and
also enhances their function (34). The responding T cells must
express IL-1R1 and different members of the IL-1 family were
shown to activate particular STATs, which leads to the expression
of relevant subset-specific transcription factors that reinforce the
polarized phenotype; IL-33 and STAT5 induce Th2, IL-1β and
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STAT3 induces Th17 and IL-18 and STAT4 induces Th1 cells (35).
Stimulatory effects of IL-1 on activation of antigen-specific CD8+
T cells, migration and killing were recently described (36). IL-1
can thus serve as an adjuvant in immunization, especially against
weak immunogens. Indeed, in some studies, IL-1β has been char-
acterized as an “endogenous adjuvant” that is generated following
immunization with adjuvants, such as CFA and aluminum hydrox-
ide (Alum) (37–39). The adjuvant properties of IL-1 in T cell
activation possibly stem from its ability to serve as a danger signal,
recruiting inflammatory cells to the site of antigen application and
inducing maturation and activation of professional APCs.
EFFECTS OF IL-1 ON HEMATOPOIESIS
Multiple hemopoietic functions have been attributed to IL-1, espe-
cially to IL-1β [reviewed in Ref. (1–7)]. The in vivo importance
of IL-1 in stimulating hematopoiesis is best demonstrated by
its ability to rescue mice after lethal irradiation or chemother-
apy, mainly via inducing recovery of the myeloid compartment
(40). IL-1 was characterized as hemopoietin-1, a factor essential
for hematopoiesis, acting by inducing the expression of recep-
tors for colony-stimulating factors (CSFs) on primitive precursor
cells (41). Of special relevance to the malignant process are the
effects of IL-1 on immature Gr-1+CD11b+ myeloid cells, also
termed myeloid-derived suppressor cells (MDSCs). MDSCs con-
sist of cells committed to differentiate in the bone marrow (BM)
into granulocytes, macrophages or dendritic cells [(reviewed in
Ref. (42)]. In cancer or chronic inflammation, MDSCs expand
in the BM in response to diverse systemic pro-inflammatory
cytokines, including IL-1β; they subsequently exit the BM as
immature cells and seed at sites of tumor/inflammation. They
also accumulate in the spleen and lymph nodes. MDSCs remain
immature and are further activated by inflammatory products to
acquire immunosuppressive and pro-invasive characteristics, the
latter mediated through secretion of VEGF and MMPs. MDSCs
mainly consist of subpopulations of granulocyte MDSCs (G-
MDSCs) and macrophage MDSCs (M-MDSCs). G-MDSCs have
a limited lifespan and usually undergo apoptosis at tumor/chronic
inflammation sites, while and M-MDSCs differentiate into M2
tumor-associated macrophages (TAMS). However, in some cases
M-MDSCs mature into M1 anti-tumor macrophages.
SIMILARITIES AND DIFFERENCES BETWEEN IL-1α AND IL-1β
Mature secreted IL-1α and IL-1β as well as Pro IL-1α bind to the
same receptors and exert the same biological activities, although
changes in the affinity of binding of these ligands to IL-1R1 have
been described. Generally, IL-1β, due to its secreted nature, has
been considered to be the major IL-1 pro-inflammatory mol-
ecule and only few comparative studies on in vivo biological
functions of both IL-1 agonistic molecules have been performed.
However, some characteristics of IL-1α and IL-1β differ dramati-
cally [reviewed in Ref. (1–7)]. IL-1β is not present in homeostatic
conditions; it is induced and secreted only upon inflammatory
signals and its secretion is tightly controlled at the levels of tran-
scription, mRNA stability, translation, and processing. On the
other hand, IL-1α is present in the cytosol, nucleus, or cell mem-
brane in homeostatic states, as well as in inflammation, when
its expression is upregulated. Importantly, IL-1α is only rarely
secreted by living cells and in most cases is undetectable in body
fluids. Previously, we demonstrated that in vivo, in steady-state
homeostasis and in inflammation, IL-1α and IL-1β are differ-
entially expressed in tissues, possibly pointing to their different
physiological roles (32, 43).
IL-1α and IL-1β differ in the sub-cellular compartments in
which they are active. IL-1β is solely active as an extracellular
secreted product, while its precursor is inactive and there is no
membrane-associated form of IL-1β. On the other hand, IL-1α
is mainly present in its cell-associated forms (ProIL-1α, IL-1NTP
and membrane-associated forms), but is only marginally secreted
in its mature from, with the exception of activated myeloid cells
[reviewed in Ref. (1–3)]. Very little is known about the biological
activity of IL-1NTP. Intracellular forms of IL-1α were shown to
translocate to the nucleus, due to a nuclear localization sequence
(NLS) located within the structure of ProIL-1α and IL-1NTP, but
lacking in the mature form of IL-1α. In cells that express ProIL-
1α, but do not secrete it, the cytokine possibly acts in an intracrine
manner from within the cell, without the need to be secreted, via
signaling pathways that are not yet fully characterized. We have
hypothesized that intracellular forms of IL-1α evolved as intra-
cellular effector molecules undertaking important homeostatic
regulatory functions beyond the realm of immunity and inflam-
mation. These include effects on gene expression, cell growth,
and differentiation, which were demonstrated in tissue-resident
cells, such as endothelial cells, fibroblasts, smooth muscle cells,
keratinocytes, epithelial cells, and brown fat cells [reviewed in Ref.
(1–3)]. Thus, IL-1α belongs to a group of “dual function”cytokines
(i.e., HMBG1 and IL-33) that are expressed in the cytosol and can
enter the nucleus, where they perform homeostatic functions, but
upon cell necrosis, they are released into the microenvironment
and serve as alarmins by inducing inflammation [reviewed in Ref.
(44, 45)].
We have hypothesized that the localization of the IL-1 mole-
cules in the context of the producing cell and its microenvironment
dictates their biological function in normal homeostasis and also
in the malignant process [reviewed in Ref. (1, 46, 47)]. Thus, as
will be shown below, membrane-associated IL-1α is immunostim-
ulatory, while cytosolic ProIL-1α controls intracrine homeostatic
functions (27, 48). However, when cytosolic ProIL-1α is released
from damaged cells, it acts as an alarmin to initiate inflamma-
tion. Secreted IL-1 (mainly IL-1β), at low local doses, induces
limited inflammatory responses followed by activation of spe-
cific immune mechanisms, while at high doses, broad inflamma-
tion accompanied by tissue-damage and tumor invasiveness are
observed.
DIFFERENTIAL ACTIVITIES OF IL-1α AND IL-1β IN THE
MALIGNANT PROCESS
In the tumor arena, IL-1 is an abundant cytokine that can
be secreted by malignant or microenvironment cells and affect
inflammation, hematopoiesis, and immunity. It is involved in all
phases of the malignant process, such as tumorigenesis, tumor
invasiveness and progression, as well as activation/suppression of
anti-tumor immunity. In the malignant process, the target cells of
IL-1 can include pre-malignant or malignant cells, as well as cells
of the microenvironment that are activated by exogenous IL-1,
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usually to produce inflammatory mediators that promote inva-
siveness. In tumorigenesis, IL-1 of microenvironment origin can
propagate initial mutations by ROS or NO, produced by phago-
cytes, other microenvironment cells, or the mutated cells. It can
then rescue initiated cells from apoptosis, enable their prolifera-
tion and further accumulation of mutations, ultimately leading to
a malignant phenotype. IL-1 can then potentiate the invasiveness
of malignant cells through stimulation of growth factors, angio-
genesis, and tumor cell motility, leading to metastasis. In some
cases, IL-1 can also enhance the immunogenicity of malignant
cells and consequently reduce tumor invasiveness. As IL-1 is an
upstream cytokine, its effects on the malignant process may be
direct or indirect, being mediated by cytokines/mediators that it
induces. Thus, at tumor sites, IL-1 induces a local cytokine network
that is determined by the array of expressed cytokines, their rela-
tive concentrations, and the expression pattern of their receptors.
This cytokine network dictates the dominant “net cytokine effect”
and it fluctuates at various phases of tumor development. We have
thoroughly studied the role of IL-1α and IL-1β in the malignant
process and have shown that in many cases they perform distinct
functions. The results of these studies are summarized below.
EFFECTS OF IL-1 ON TUMORIGENESIS
Tumorigenesis encompasses the in vivo induction of tumors cells
by carcinogens or oncogenes, as well as in vitro transformation
of normal or immortalized non-tumor forming cells into overt
malignant cells that are capable of tumor formation in mice.
CONSTITUTIVE EXPRESSION OF IL-1β IN THE STOMACH CAN RESULT IN
TUMORIGENESIS
The overexpression of human IL-1β fused to a signal peptide (ssIL-
1β), in mouse stomach epithelial cells leads to development of
spontaneous gastric inflammation, pre-neoplastic lesions, and in
some cases, tumors. Thus, secreted IL-1β serves as both an initia-
tor and a tumor promoter (49). This correlates with recruitment
of MDSCs to the stomach and their in situ activation through the
IL-1R1/NF-κB pathway. Gastric pre-neoplasia and MDSC mobi-
lization were inhibited by the IL-1Ra. In this system, overexpressed
levels of IL-1β in the stomach induced a strong local inflammatory
response,driven by continuous NF-κB activation, which promoted
extensive hyperplasia and subsequent tumorigenesis. The ssIL-1β
construct, driven by the elastase promoter in the pancreas, resulted
in severe chronic pancreatitis; the severity of lesions and local
inflammation correlated to the extent of IL-1β expression (50). In
this system, older mice developed acinar-ductal metaplasia, but no
tumor development was observed.
LOCAL EXPRESSION OF IL-1β IS INVOLVED IN CHEMICAL
CARCINOGENESIS
We have demonstrated the role of host-derived IL-1 mole-
cules on susceptibility to chemical carcinogenesis induced by
3-methylcholanthrene (3-MCA), which acts both as an initiator
and a tumor promoter, using a battery of IL-1 KO mice [IL-1α−/−,
IL-1β−/−, IL-1α/β−/− (double KO mice), or IL-1Ra−/− mice] in
comparison to wild-type (WT) mice (51). We found that defi-
ciency of IL-1β leads to delayed 3-MCA-induced fibrosarcoma
development. In mice deficient in IL-1β, tumors appeared only
after a prolonged lag period and developed only in part of the
treated mice. In WT and IL-1α−/− mice, carcinogenesis patterns
were similar and all mice developed tumors. In IL-1Ra−/−mice, in
which unattenuated levels of the IL-1 molecules are present, tumor
development was more rapid than in WT mice. An early inflam-
matory response consisting of neutrophils was detected as early
as 10 days after carcinogen injection. At later times, when tumor
cells are already apparent, the local infiltrate consisted mainly of
macrophages, which is consistent with the role of macrophages in
tumor progression (52–54). Patterns of inflammation correlated
with tumor development. Thus, in mice deficient in IL-1β, almost
no inflammatory response was observed during tumor develop-
ment, lack of IL-1α did not impair inflammation as compared to
WT mice, while an heightened inflammatory response was evi-
dent in IL-1Ra KO mice. These results indicated for the first time
that 3-MCA-induced carcinogenesis is inflammation-dependent,
as previously it had been suggested that tumor development is
controlled by immune surveillance mechanisms that eliminate the
arising malignant cells [reviewed in Ref. (55)].
CONSTITUTIVE EXPRESSION OF IL-1α IN THE SKIN INITIATES BENIGN
SKIN PAPILLOMAS
The role of wound healing in tumorigenesis has recently been
reviewed (56, 57). In mice specifically over-expressing a trans-
gene of MAPK kinase 1 in the suprabasal layer of the skin,
where non-proliferating but differentiating keratinocytes reside,
keratinocyte-derived IL-1α initiates wound-induced papilloma
formation (58). In such mice, hyperproliferative epidermis and a
chronic inflammatory infiltrate were observed. However, papillo-
mas developed only upon skin wounding. In normal keratinocytes
IL-1α is present constitutively in the cytosol and its expression
increases in cells expressing the MAPK kinase 1 transgene, but it is
not released into the microenvironment. Following a skin wound,
IL-1α is released from dying cells and activates an inflammatory
response in the suprabasal layer by infiltration of macrophages and
γδT. Subsequently, immature keratinocytes are recruited into the
suprabasal layer where they proliferate, leading to the development
of benign tumors. Treatment with dexamethasone, which impairs
cytokine production and cell infiltration, or with IL-1Ra, dramat-
ically reduced the local inflammation and papilloma formation.
IL-1β is not involved in wound-induced papilloma formation.
THE ALARMIN FUNCTION OF IL-1α CONTRIBUTES TO
CARCINOGEN-INDUCED LIVER CARCINOGENESIS
In a model of diethylnitrosamine (DEN)-induced liver carcino-
genesis in mice lacking p38α in hepatocytes, the activity of the
carcinogen is enhanced as compared to that in WT mice. This is
due to enhanced ROS accumulation in hepatocytes, hepatocyte
cell death, and liver damage, which ultimately culminates in car-
cinogenesis. IL-1α is homeostatically expressed in hepatocytes and
is released from dying hepatocytes; it stimulates local inflamma-
tory responses, as well as a compensatory proliferative response
that characterizes the regenerating liver. These events contribute
to the development of hepatocellular carcinoma (HCC) (59). Inhi-
bition of IL-1α or ablation of IL-1R1 prevents HCC development.
In this model, IL-1α-induced IL-6 activates STAT3 and promotes
liver regeneration and tumor outgrowth (60, 61). Similar effects
Frontiers in Immunology | Inflammation July 2013 | Volume 4 | Article 177 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Voronov et al. IL-1 in the tumor microenvironment
were observed during gastric neoplasia in mice with a conditional
knockout of IKKβ (lack of NF-κB signaling) in gastric epithe-
lial cells (GECs) after exposure to stress induced by Helicobacter
felis infection or ionizing irradiation (62). This resulted in a local
accentuated inflammatory response, manifested by increased ROS
production, tissue damage, apoptosis followed by cell necrosis,
and release of IL-1α from GECs. This inflammatory response
ultimately resulted in rapid progression to gastric pre-neoplasia,
which was inhibited by blocking IL-1 signaling.
ENDOGENOUS EXPRESSION OF IL-1α IN ONCOGENE-TRANSFORMED
CELLS FACILITATES THEIR INVASIVE POTENTIAL
Several oncogenes, including Ras, Myc, and Ret not only mediate
neoplastic transformation, but also activate intrinsically inflam-
matory cytokines that establish the pro-invasive tumor microen-
vironment [reviewed in Ref. (63)]. Thus, in a model of two-stage
skin carcinogenesis (DMBA/TPA), mutated Ras appears early in
initiated cells, whereas inflammation induces tumor promotion.
Mice lacking IL-1R1 or MyD88 are less sensitive to topical skin
carcinogenesis (64). The role of IL-1 in acquiring the malignant
phenotype of Ras transformed primary keratinocytes was studied.
It was shown that Ras-transduced keratinocytes concomitantly
express IL-1α that acts in an autocrine loop together with IL-1R
and MyD88. This loop controls defects in keratinocyte differentia-
tion that are observed in papillomas and skin malignancies, as well
as NF-κB activation. Treatment with IL-1Ra, reversed the differ-
entiation defects and inhibited pro-inflammatory gene expression
in keratinocytes, indicating that IL-1α is secreted from the cells
and then activates them in an autocrine manner through IL-1R1
(64). Similar findings were found in a model of pancreatic ductal
carcinoma (PDAC), in which constitutive K-ras and NF-κB acti-
vation are characteristic. In this model, early mutation activation
of K-ras occurs, but the pathways leading to NF-κB activation are
not clear. Mutated Ras induces an IL-1α-dependent mechanism
that leads to constitutive NF-κB activation and tumor promotion
(65). Thus, mutated K-ras induces AP-1 that subsequently acti-
vates IL-1α expression/secretion, which further leads to NF-κB
activation in an autocrine manner, resulting in expression of its
target genes, ultimately leading to PDAC development and inva-
siveness. Constitutive NF-κB activity is mediated by feed-forward
loops activated by two NF-κB target genes: IL-1α and p62 – an
adaptor protein that prolongs NF-κB activation by intervening in
K63-polyubiquitination, which are both constitutively induced as
a result of NF-κB activation and further fuel its constant activation.
IL-1β is not involved in this regulatory circuit. These results sub-
stantiate the significance of the NF-κB/IKKβ pathway as a key link
between inflammation and cancer, inducing pro-inflammatory
cytokines in myeloid cells and anti-apoptotic pathways in epithelial
cells [reviewed in Ref. (66, 67)]. The mechanisms of unique induc-
tion of either IL-1α or IL-1β in initiated cells are still unknown and
are possibly dependent on the cell type.
TUMOR CELL- OR HOST-DERIVED IL-1α PREFERENTIALLY
ACTIVATES ANTI-TUMOR CELL IMMUNITY
ANTI-TUMOR EFFECTS OF CELL-ASSOCIATED IL-1α
We demonstrated the anti-tumor effects of IL-1α expression
by malignant cells in different experimental systems, using
oncogene-transformed fibroblasts that constitutively express IL-
1α, possibly due to alterations in the control of IL-1α expression
induced by the oncogene. Fibrosarcoma cells were transfected with
cDNA of ProIL-1α and lymphoma cells were induced to express IL-
1α in a transient manner, following in vitro activation of the cells
with immunomodulators/cytokines (68–73). In these cell lines,
IL-1α is expressed in the cytosol or on the membrane, but is not
secreted. In such cells, IL-1β is not expressed. IL-1α-expressing
tumor cells usually fail to cause tumor development in intact mice
but if tumors occur, they subsequently regress. Tumor regression in
this instance is mainly mediated by CD8+ T cells, with some con-
tribution of NK cells and macrophages. Regression of tumors from
IL-1α-positive fibrosarcoma cells does not require activation of
CD4+ T cells, which suggests that cell-associated IL-1α may act as
a membrane-associated co-stimulatory molecule or focused adju-
vant that directly activates CD8+ T cells. Tumor cell-associated
IL-1α also potentiates antigen presentation by the malignant cells
themselves, possibly through IFNγ-induced MHC class II expres-
sion, and also via cross-presentation by professional APCs. Tumor
regression induces a long-term specific immune memory that
protects mice against a challenge with violent parental cells.
Tumor cell-associated IL-1α was shown to be effective in tumor
cell vaccines used to intervene in the growth of tumor cells of the
corresponding violent line (non-IL-1 expressing). Thus, the vac-
cine induced regression of violent fibrosarcomas when applied
at a critical “therapeutic window” 5–10 days (single application
of Mitomycin-C-treated tumor cells) after inoculation of the
malignant cells (70).
The“natural”membrane-associated form of IL-1α is important
for exerting anti-tumor effects, as it acts as an adhesion-molecule,
allowing efficient cell-to-cell interactions between malignant and
immune effector cells that bear IL-1Rs, which enables better
killing. Membrane IL-1α is also effective as a focused adjuvant that
efficiently acts at low levels of expression, below those which are
toxic to the host. Other studies have also emphasized the effec-
tiveness of membrane-associated cytokines expressed on engi-
neered tumor cells (i.e., IFNγ, GM-CSF, M-CSF, TNFα, and IL-12)
(74–76).
HOST-DERIVED IL-1α IS ESSENTIAL FOR IMMUNOEDITING DURING
CARCINOGENESIS
We have shown that patterns of IL-1 expression in the microen-
vironment can affect the immunogenicity of the arising malig-
nant cells during tumorigenesis. Immunoediting has mainly been
studied in the process of experimental carcinogenesis induced
by 3-MCA. Thus, we have shown that transplantable 3-MCA-
induced fibrosarcoma cell lines obtained from IL-1α−/− mice
failed to induce tumors in immune intact mice, whereas in sub-
lethally irradiated mice, tumors do develop (77). This is despite
the fact that tumor incidence and the nature of the local inflam-
matory response were comparable in 3-MCA-treated IL-1α−/−
mice and WT mice. Impaired immunoediting occurs in 3-MCA-
induced tumors in various immunodeficient mice that lack crit-
ical components essential for the development of anti-tumor
cell immunity. These include mice lacking immunosurveillance
cells, such as Rag2−/− mice, which lack T cells and B cells, nude
mice, CD1d−/− mice, which lack CD1d-restricted T cells, and
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Ja18−/− mice, lacking semi-invariant NKT cells or mice deficient
in cytokines critical for anti-tumor immunity, such as IFNγ and
IL-12 [reviewed in Ref. (55, 78)]. IL-1α can now be added to the list
of cytokines of importance in immunoediting. It is not yet known
which form of IL-1α (secreted or cell-associated) is involved in
the process of immunoediting. The process of immunoediting in
immunodeficient hosts allows the survival of malignant cell vari-
ants, which are “universally immunogenic,” as they express surface
adhesion or co-stimulatory molecules (i.e., ICAM-1 or 2, LFA-1
or 3, CD1d, VLA-4, B7 etc.) that are essential for the development
of anti-tumor immunity. Thus, IL-1α−/− cell lines were shown to
express more surface MHC class I molecules, co-stimulatory mol-
ecules (i.e., B7.1 and B7.2) as well as adhesion molecules, such as
L-selectin and ICAM-1, as compared to fibrosarcoma cells from
WT mice. IL-1α−/− immunogenic cells are rejected in intact mice
by conventional innate and specific anti-tumor immune effector
cells, including NK cells, as well as by CD4+ and CD8+ T cells.
Immune impairments in IL-1α−/−mice, including in NK develop-
ment and in the killing capacity of NK cells, LAK cells, and CTLs,
were characterized. The role of IL-1α in activation of immunosur-
veillance cells was shown in transgenic mice over-expressing IL-1α
in the skin (79). In such mice, DMBA/TPA treatment induced skin
tumors at very low incidence compared to WT mice, due to the
rapid eradication of arising malignant cells by innate effector cells
activated by local IL-1α in the skin. We hypothesize that IL-1α in
the tumor microenvironment is immunostimulatory, rather that
inflammatory, due to its localization on the surface of cells and
its limited secretion, as compared to IL-1β. However, when IL-1β
levels in tissues are limited, it can also be immunostimulatory, as
will be shown below.
TUMOR CELL- OR HOST-DERIVED IL-1β IS INVOLVED IN
TUMOR INVASIVENESS
IL-1β SECRETED BY MALIGNANT CELLS INCREASES THEIR INVASIVE
POTENTIAL AND INDUCES TUMOR-MEDIATED IMMUNE SUPPRESSION
To assess effects of tumor cell-associated IL-1β on tumorigenic-
ity patterns, we transfected violent fibrosarcoma cells with con-
structs bearing the cDNAs of the mature form of IL-1β or the
mature form of IL-1β ligated to a signal sequence (ssIL-1β),
to induce potent secretion of IL-1β through the endoplasmic
reticulum-Golgi pathway (80, 81). We found that IL-1β- and ssIL-
1β-transfected fibrosarcoma tumors were more invasive than the
violent parental cells or mock-transfected cells. The invasiveness
of the malignant cells correlated with the amount of IL-1β that was
secreted by them. In addition, only the ssIL-1β transfectants, which
secrete relatively high levels of the cytokine, exhibited a metastatic
potential. Enhanced angiogenesis patterns, as evidenced by high
vessel density in tumors and increased secretion of VEGF by the
malignant cells, were observed in tumors secreting IL-1β. Sim-
ilar observations were described in other experimental systems
using IL-1β-transfected tumor cells (82–84). No anti-tumor effec-
tor cells or cytokines that potentiate anti-tumor immunity (i.e.,
IFNγ and IL-2) could be detected in spleens of mice injected with
fibrosarcoma cells transfected with IL-1β or ssIL-1β or with the
violent parental cells. In contrast, effective anti-tumor cell immune
responses were observed in mice injected with fibrosarcoma cells
transfected with ProIL-1α, as indicated above.
Further studies have shown that general anergy develops in
mice bearing tumors of IL-1β secreting cells, mediated by MDSCs
(80, 82, 85). Resection of large tumors of IL-1β secreting cells
completely restored immune reactivity and reversed the MDSC
response within 7–10 days. Treatment of tumor-bearing mice with
the IL-1Ra reduced tumor growth and attenuated the MDSC
response.
In spite of tumor-mediated suppression, resection of large
tumors of IL-1β secreting cells, followed by a challenge (2 months
after tumor resection) with the violent parental cells induced resis-
tance in mice; protection was not observed in mice bearing tumors
of mock-transfected fibrosarcoma cells. Thus, in mice bearing
tumors of IL-1β secreting cells, anti-tumor cell specific immunity
is activated, due to the adjuvant-like effects of IL-1β; however, pro-
tective immunity is not manifested, due to suppression of immune
effector mechanisms. It is notable that when tumor cells express-
ing membrane-associated IL-1α are injected into mice, anti-tumor
immune responses occur without concomitant tumor-mediated
suppression and thus the malignant cells are rejected.
TUMOR-MEDIATED ANGIOGENESIS IS LARGELY
STIMULATED BY MICROENVIRONMENT IL-1β
We have studied in detail the role of IL-1β in tumor-mediated
angiogenesis, which is almost non-existent upon injection of
tumor cells into IL-1β KO mice or following neutralization of
IL-1β in WT mice (86, 87). Inflammation usually accompa-
nies tumor-mediated angiogenesis. We have used B16 melanoma
cells encapsulated in Matrigel plugs, in order to characterize
cell/cytokine interactions in the early angiogenic response (88).
We have characterized a newly described auto-induction circuit in
which IL-1β and VEGF interact and induce each other. Tumor-
mediated angiogenesis is inhibited if either IL-1β or VEGF are
neutralized and it does not occur in IL-1β KO mice. The IL-
1β and VEGF circuit acts via interactions between BM-derived
VEGFR1+/IL-1R1+ immature myeloid cells (MDSCs) and tissue-
resident endothelial cells. Myeloid cells do not directly stimulate
endothelial cells for migration and subsequent blood vessel for-
mation. However, myeloid cells produce IL-1β and a network
of pro-inflammatory cytokines/molecules, which subsequently
activate resting endothelial cells to produce VEGF, as well as
other direct pro-angiogenic factors. Subsequently, VEGF activates
endothelial cells for blood vessel formation. IL-1β thus provides
the inflammatory microenvironment for angiogenesis and tumor
progression. We have shown that IL-1β inhibition stably reduces
tumor growth, by limiting inflammation and by inducing the mat-
uration of MDSCs into M1 macrophages, which do not promote
tumor invasiveness and can be cytotoxic/cytostatic for tumor cells
and can also serve as APCs that induce anti-tumor immunity.
Thus, this study has characterized IL-1β as a major mediator in
the tumor microenvironment that recruits MDSCs and also con-
trols their immature pro-invasive and immunosuppressive state;
ablation of IL-1β alters the pro-tumor microenvironment into an
anti-tumor one.
MICROENVIRONMENT IL-1 ACTIVATES CANCER STEM CELLS
In murine tumor models and in cancer patients, it was shown that
IL-1β increases tumor invasiveness [reviewed in Ref. (1, 46, 47)].
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Recently, direct effects of IL-1β on cancer stem cells (CSCs) or the
niche that favors CSC formation were described. In in vitro stud-
ies, recombinant IL-1β increased the sphere forming capacity of
CSCs and enhanced expression of stemness genes (i.e., Bmi1 and
Nestin), as well as Zeb1 that is an important regulator of EMT and
self-renewal (89). Furthermore, the Weinberg group has described
a circuit in which carcinoma-derived IL-1 creates the niche for
the transition of “regular tumor cells” into CSCs (90). Thus, in
the tumor microenvironment, carcinoma-derived IL-1 (IL-1α and
IL-1β) activates mesenchymal stem cells (MSCs) to produce PGE2
and other cytokines, such as IL-6, IL-8, Gro-α, and RANTES that in
turn act on the carcinoma cells and induce activation of β-catenin
and transition into CSCs. These effects were largely neutralized by
the IL-1Ra or siRNAs against IL-1α and IL-1β. Thus, IL-1 in the
tumor microenvironment can support development and expan-
sion of CSCs and thus amplify the malignant process and support
metastasis formation.
ANTI-TUMOR EFFECTS OF MICROENVIRONMENT IL-1β IN MICE WITH
MINIMAL RESIDUAL DISEASE
Elegant studies by the Zitvogel group demonstrated that tissue-
damage following cancer treatment with some chemotherapeu-
tical drugs activates DCs in the tumor microenvironment to
present tumor antigens and further stimulate anti-tumor immu-
nity that synergizes with the chemotherapy (91). In the milieu
of anthracycline-treated tumors, the NLRP3 inflammasome is
activated and stimulates IL-1β production that is essential for
activating IFNγ producing CD8+ T cells. In addition, patients
with breast cancer with a loss-of-function allele of P2X7R, which
is essential for activation of the NLRP3 inflammasome and IL-1β
processing/secretion, develop a more rapid metastatic disease than
individuals with the normal allele. This may represent a unique
scenario in which a low tumor burden, possibly accompanied by
relative low levels of IL-1β in the microenvironment could activate
local immunity. These results will hopefully open new avenues for
use of IL-1β, and possibly also IL-1α, in cancer immunotherapy in
tumor-debulked patients.
INTERACTIONS BETWEEN TUMOR CELL- AND
MICROENVIRONMENT-DERIVED IL-1 IN THE CONTROL OF
TUMOR INVASIVENESS OF 3-MCA-INDUCED TUMOR CELL
LINES
In the tumor microenvironment, interactions between IL-1
derived from the malignant cells or from inflammatory cells inter-
act and determine the invasive potential of the tumor. Transplan-
tation assays, in which 3-MCA-induced fibrosarcoma cell lines that
were derived from WT or IL-1 KO mice were injected into the same
strains of mice, enabled us to define the role of IL-1 expressed by
the malignant cells or the microenvironment in tumor progression
(51, 77, 92–94).
3-MCA-induced fibrosarcoma cell lines from WT mice mani-
fested low invasiveness in IL-1 deficient mice, intermediate inva-
siveness in WT mice, and high invasiveness in IL-1Ra−/− mice,
pointing to the importance of microenvironment-derived IL-1 in
tumor progression. The contribution of tumor cell-derived IL-
1 was demonstrated following injection of 3-MCA fibrosarcoma
cell lines from IL-1 KO mice into WT mice. Thus, fibrosarcoma
cells obtained from mice deficient in IL-1β failed to grow in WT
mice, due to their inability to recruit a local inflammatory response
that is essential for tumor invasiveness. Furthermore, invasive
3-MCA-induced fibrosarcoma cells from IL-1Ra KO mice were
only weakly tumorigenic in IL-1 deficient mice (92–94). We sug-
gest that initially, upon injection of tumor cells into mice, the
malignant cells express relatively small amounts of IL-1 that sub-
sequently induces broad inflammation mediated by infiltrating
cells, ultimately leading to tumor invasiveness. In malignant cells,
IL-1 can be constitutively expressed due to oncogene activation
or it can be induced by danger signals in the microenviron-
ment. IL-1 of the microenvironment is critical to induce tumor
outgrowth and progression leading to invasiveness of 3-MCA
fibrosarcomas.
In naturally occurring tumor cells, both IL-1 molecules can
be expressed and interact. The expression of IL-1α in 3-MCA-
induced tumor cells from IL-1β KO mice concomitantly activated
a strong T helper and CTL response, which also contributed to the
reduced in vivo growth of these cells in WT mice. When cell lines
from IL-1α KO mice were injected into mice, progressive tumor
growth occurred, due to the pro-invasive and immunosuppressive
effects of tumor cell-derived IL-1β and the absence of immunos-
timulatory effects of tumor cell-associated IL-1α that is missing in
these cells. Cell lines that originated in 3-MCA-treated IL-1Ra−/−
mice were very invasive and metastatic, compared to cell lines
originating in WT mice, due to high-unattenuated levels of IL-1
expression in the malignant cells, which facilitates their invasive-
ness and also promotes immunosuppressive mechanisms. Thus,
fibrosarcoma cell-derived IL-1α and IL-1β do not act in concert
and each IL-1 molecule has unique effects on tumor invasiveness
or on anti-tumor cell immune responses. At tumor sites, immuno-
suppressive effector cells, induced by excessive expression of IL-1β
inhibit or mask the induction/function of anti-tumor immuno-
surveillance induced by tumor cell-derived IL-1α. At tumor sites,
effects of tumor-derived IL-1 and host-derived IL-1 interact and
modulate tumor progression. Elucidation of these interaction pat-
terns should enable better understanding of the overall role of IL-1
in the malignant process.
COMPLEX EFFECTS OF IL-1 ON THE INVASIVENESS OF
HUMAN TUMORS
In experimental tumor models in WT mice and in cancer patients,
increased local levels of IL-1 at tumor sites usually correlate
with tumor invasiveness and a bad prognosis [reviewed in Ref.
(1, 46, 47)]. Very little is known about interactions between
IL-1α and IL-1β expressed at tumor sites by either the malig-
nant or microenvironment cells. Most studies usually assess only
one of the IL-1 agonistic molecules and do not discriminate
between patterns of its expression in the malignant cells versus
the microenvironment. The levels of IL-1 expression at tumor
sites are also not compared to homeostatic levels in the given
organ. Thus, insufficient characterization of IL-1 at tumor sites
has led to some inconsistencies concerning the impact of the
concerted action of IL-1α and IL-1β on the malignant process.
For example, Okamoto et al. showed constitutively active NLRP3
inflammasome and IL-1β secretion in melanoma cell lines derived
from late stage patients, where selection for cells expressing
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FIGURE 1 | Effects of IL-1 at tumor sites. IL-1 can be produced at tumor
sites by the malignant cells or by diverse cells in the tumor
microenvironment. IL-1 generated by tumor cells can affect the malignant
cells in an autocrine or paracrine manner, enabling proliferation, and
invasiveness. In parallel, IL-1 secreted by malignant cells activates
microenvironment residing or infiltrating cells to produce additional IL-1,
which then induces a cytokine network, which further activates tumor
invasiveness. High doses of IL-1 at tumor sites usually result in an invasive
potential and immunosuppression. Expression of IL-1α on the membrane
of malignant cells increases their immunogenicity and leads to induction
of efficient anti-tumor responses. Membrane IL-1α expressed on
infiltrating cells possibly also promotes the development of anti-tumor cell
immunity. Low levels of IL-1 at tumor sites at early stages of tumor
development or upon IL-1 attenuation, usually result in efficient anti-tumor
immunity, in the absence of immunosuppression mainly mediated by
IL-1-induced MDSCs and also Tregs. When immunosuppression is evident
at tumor sites, it hinders the development or masks the function of
anti-tumor immunity and thus invasive growth results. Host- and tumor
cell-derived IL-1 induce each other and together fuel the local, and
sometimes systemic, inflammatory response. Intracellular ProIL-1α in
tumor cells induces intracrine functions following translocation into the
nucleus. These are related to survival, proliferation, or gene expression;
however, they were not sufficiently characterized in the context of the
malignant process.
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invasiveness-promoting molecules had already occurred. This
can also explain the increased invasive phenotype of progres-
sive melanoma tumors (95). In a different study on melanoma
patients performed by the Grimm group, IL-1α was expressed in
most primary tumors (98%) and approximately half (55%) of
metastases. IL-1α was also expressed in 73% of inspected nevi. IL-
1β was expressed in approximately 10% of primary or metastatic
melanoma samples, but its expression strongly correlated with
IL-1α expression (96). The mechanisms of preferential IL-1α
expression in human melanomas are not known. By using cell lines
obtained from human melanoma patients, typical molecular path-
ways of inflammation, including secretion of ROS, NO, COX-2, as
well as NF-κB and c-Jun activation, were observed in malignant
melanoma cells upon activation by endogenous IL-1, which also
promotes in vitro cell proliferation. These effects were most pro-
nounced in cell lines producing significant amounts of IL-1 and
were abrogated by antibodies against IL-1R1 or siRNA of IL-1α
and IL-1β. Furthermore, blocking IL-1 signaling in melanoma
cell lines induced autophagy, which might further lead to cell
death. IL-1 secreted by melanoma cells also affects recruitment
and activation of inflammatory cells at tumor sites, which con-
tribute to invasiveness. The correlation between IL-1 expression
in tumors and its secretion is still unknown and awaits further
investigation.
FUTURE PROSPECTS FOR IL-1 MANIPULATION IN
ANTI-TUMOR THERAPIES
The network of cytokines and immune/inflammatory cells in
the tumor microenvironment controls the fate of the malignant
process. In the tumor microenvironment, the balance between the
“wound healing” type of inflammation, which promotes tumor
progression and immune escape, and “favorable” limited inflam-
matory responses, in which professional APCs are activated and
induce anti-tumor adaptive immunity, determines the direction
of the malignant process [reviewed in Ref. (97–101)]. Due to the
plethora of activities of IL-1 in the malignant process and its dom-
inant role in determining local cytokine networks at tumor sites,
neutralization of IL-1 as a single target molecule has potential to
tilt the balance between destructive inflammation and protective
anti-tumor immunity in the tumor microenvironment (Figure 1).
For example, we have shown that 4T1 cells produce invasive and
metastatic breast tumors which grow progressively in WT mice,
whereas, they cause tumors that grow initially but later regress in
IL-1 KO mice, due to the efficient induction of a CTL-mediated
anti-tumor response in these mice.
Use of genetically engineered cells or mice with distinct patterns
of IL-1 expression, have shown that IL-1α and IL-1β have dis-
tinct effects at tumor sites. Thus, IL-1β promotes invasiveness and
immunosuppression, while IL-1α is mainly immunostimulatory.
This is true for both tumor cell-derived or microenvironment-
derived IL-1. Immunosuppression induced by IL-1β usually
acts in a dominant manner and masks the immunostimulatory
anti-tumor effects of IL-1α.
However, in “real-life” both IL-1 molecules are usually
expressed and they induce each other. Further studies should
establish the “IL-1 map” in individual tumors, taking into account
patterns of expression, secretion, and levels of IL-1α and IL-1β in
malignant or infiltrating cells. Having these data should facilitate
the design of treatment protocols based on IL-1 manipulation.
IL-1 neutralization agents are available at the present time
(102–104). Thus, the IL-1Ra, also called Anakinra (Kineret;
Amgen/Biovitrum) is FDA-approved and has been shown to be
safe and efficient in alleviating symptoms of rheumatoid arthritis
and auto-immune diseases. Characterization of the inflamma-
some pathway of IL-1β processing and secretion encouraged the
development of novel anti-IL-1 agents that are now being tested
in different clinical trials in diverse diseases with inflammatory
manifestations. Some of these trials have produced initial promis-
ing results. These agents now await testing in cancer patients,
once protocols are established for their integration into first-line
anti-tumor therapies. Optimally, IL-1 neutralization should be
most effective in patients with minimal residual disease (MRD),
to prevent tumor recurrence and metastasis. In such patients,
tumor-mediated immunosuppression and inflammation should
be reduced and enable induction of protective anti-tumor immune
responses in a microenvironment that does not favor invasive-
ness. These treatments may be given for extended periods, to
convert MRD to a chronic state, provided that resistance to anti-
IL-1 therapy does not develop. Neutralization of tumor-associated
IL-1, especially IL-1β, should not be complete, in order not to
compromise the immune system of patients. In addition, due
to the adjuvanticity of cell-associated IL-1α, tumor cell vaccines
based on constitutive or transient IL-1α expression has the poten-
tial to induce anti-tumor cell immunity in patients with MRD.
In such patients, one can envision initial systemic neutraliza-
tion of IL-1β followed by application of IL-1α expressing tumor
cell vaccines. In conclusion, better understanding the integrative
role that IL-1α and IL-1β play in animal experimental models
and in cancer patients, together with “IL-1 mapping” at tumor
sites, as indicated above, should pave the way for safe and effi-
cient application of anti-IL-1 therapies at the bedside for cancer
patients.
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